Dr. Amer Zeidan عامر زيدان

05/23/2025

We have just filed a complaint and a motion for a temporary restraining order will follow. As we pursue legal remedies, we will do everything in our power to support our students and scholars. We have just filed a complaint and a motion for a temporary restraining order will follow. As we pursue leg...

02/15/2024

https://www.facebook.com/share/p/UARYmiJwT1edHVUP/?mibextid=Nif5oz

09/25/2023

Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.

04/18/2023

03/26/2023

08/04/2022

Many thanks to ASH clinical News for highlighting our most recent Blood paper

Treatment responses and survival outcomes were comparable among older, unfit patients with acute myeloid leukemia (AML) who received either of two hypomethylating agents (HMAs), azacitidine or decitabine, according to research findings published in Blood.

03/09/2022

January 27, 2022Speaker: Prof. Amer Zeidan